Green Journals

International Approved Journals

Journal Information

Journal Title	CANCER CHEMOTHERAPY AND PHARMACOLOGY
Publisher	SPRINGER
ISSN	0344-5704
E-ISSN	1432-0843
Database	Clarivate
Domain	Health Sciences, Life Sciences, Physical Sciences

Classification History

Year	A+	A	B	C
2026		✓	✓	
2025		✓	✓	
2024		✓	✓	
2023		✓	✓	
2021/2022		✓	✓	
2020		✓	✓	
2019		✓	✓	
2018		✓		

Classification: The table above shows all journal classifications recorded for each classification year in the Green Journals database. A journal may have more than one classification in the same year.

Recent Articles

Impact of adverse events on survival outcomes in patients treated with CDK4/6 inhibitors for advanced breast cancer
2025-12 Vol. 95 Issue 1
Authors: Martina Catalano, Gestiana Cekrezi, Irene De Gennaro Aquino et al.
DOI: 10.1007/s00280-025-04836-y

Presence of drug-drug interactions between esomeprazole and an ALK tyrosine kinase inhibitor (Dirozalkib)
2025-12 Vol. 95 Issue 1
Authors: Lin Fang, Xin Jiang, Kexiu Song et al.
DOI: 10.1007/s00280-025-04837-x

Association of DPYD rs4294451, plasma uracil concentration, and sex with 5-fluorouracil exposure in patients with gastrointestinal cancer
2025-12 Vol. 95 Issue 1
Authors: Gabriel A. Brooks, Dylan B. Ness, Kathryn C. Hourdequin et al.
DOI: 10.1007/s00280-025-04851-z

6-gingerol alleviates chemotherapy-induced nausea and vomiting by inhibiting ferroptosis via the regulation of iron homeostasis
2025-12 Vol. 95 Issue 1
Authors: Wan Liang, Lei Feng, Siyu Han et al.
DOI: 10.1007/s00280-025-04850-0

Mechanisms of resistance to antibody-drug conjugates in cancer: molecular barriers and pharmacological solutions
2025-12 Vol. 95 Issue 1
Authors: Lina Eltaib, Muhammad Afzal, Chandana Maji et al.
DOI: 10.1007/s00280-025-04848-8

Potential clinical relevance of rare dihydropyrimidine dehydrogenase genetic variants identified using whole-exome NextGen sequencing in cancer patients with severe fluoropyrimidine toxicity
2025-12 Vol. 95 Issue 1
Authors: Elizabeth Cui, Samantha Medwid, Ute I. Schwarz et al.
DOI: 10.1007/s00280-025-04839-9

Lack of effects of S-equol-containing supplement on the pharmacokinetics of oral hormone therapy drugs for breast cancer
2025-12 Vol. 95 Issue 1
Authors: Takehiko Sambe, Chiyo K. Imamura, Noriko Hida et al.
DOI: 10.1007/s00280-025-04852-y

Benefit of plasma cystatin C for carboplatin individual dosing in a patient with spinal amyotrophy
2025-12 Vol. 95 Issue 1
Authors: Matthieu Gracia, Sabrina Marsili, Julien Vintejoux et al.
DOI: 10.1007/s00280-025-04847-9

Pharmacokinetic comparison of cisplatin administration via HIPEC and intravenous infusion in a porcine model
2025-12 Vol. 95 Issue 1
Authors: Christina Harlev, Elisabeth Krogsgaard Petersen, Mats Bue et al.
DOI: 10.1007/s00280-025-04843-z

Selection of isatuximab dosing regimen in pediatric patients with leukemia using population pharmacokinetics
2025-12 Vol. 95 Issue 1
Authors: Claire Brillac, Dorothée Sémiond, Corina Oprea et al.
DOI: 10.1007/s00280-025-04832-2